
POLYRIZON LTD
PLRZ · NASDAQ
Updated at 2026-10-13 15:18:11
- Today's High
- $9.39
- Today’s Low
- $8.07
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $9.05
- Previous Close
- $9.05
- Volume
- 6.41K
- Market Cap
- $21.46M
- P/E Ratio
- --
- EPS
- $-5.63
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 5 HAPNINA STREET, RA'ANANA, ISRAEL, 4321545
- Country
- IL
- Listing Date
- 2024-10-29
- Fiscal Year End
- December
- Shares Outstanding
- 2.08M
- CIK
- 0001893645
- Website
- polyrizon-biotech.com
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company is headquartered in Ra'anana, Israel.
Financial Metrics
Revenue
2026-06-30
--
2025-12-31
--
2025-09-30
--
2025-06-30
--
Operating Expenses
2026-06-30
$4.17M
2025-12-31
$3.61M
2025-09-30
$1.88M
2025-06-30
-$1.24K
Net Income
2026-06-30
-$1.42M
2025-12-31
-$3.15M
2025-09-30
-$176.82K
2025-06-30
-$88.5
Net Profit Margin
2026-06-30
--
2025-12-31
--
2025-09-30
--
2025-06-30
--
Earnings Per Share
2026-06-30
--
2025-12-31
--
2025-09-30
--
2025-06-30
$-0.74
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$4.17M
2025-12-31
-$3.61M
2025-09-30
-$2.4M
2025-06-30
-$1.14K
Effective Tax Rate
2026-06-30
--
2025-12-31
--
2025-09-30
--
2025-06-30
--
| Item | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Operating Expenses | $4.17M | $3.61M | $1.88M | -$1.24K |
| Net Income | -$1.42M | -$3.15M | -$176.82K | -$88.5 |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | -- | -- | -- | $-0.74 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$4.17M | -$3.61M | -$2.4M | -$1.14K |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.